Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31870260,distribution,"The main distribution of the drug was in fat (15067 ± 801 ng/ml) and liver (13647 ± 1126 ng/ml), and the kidney was the primary excretion route (4.47%-11.94%).",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[ng] / [ml],15067,5686,DB00292,Etomidate
,31870260,distribution,"The main distribution of the drug was in fat (15067 ± 801 ng/ml) and liver (13647 ± 1126 ng/ml), and the kidney was the primary excretion route (4.47%-11.94%).",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[ng] / [ml],13647,5687,DB00292,Etomidate
,31870260,Cmax,"The Cmax after injection with 1.045 mg/kg, 2.09 mg/kg, and 4.18 mg/kg was 1476.5 ± 138.9 ng/ml, 2846.1 ± 223.3 ng/ml, and 6233.3 ± 238.9 ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[ng] / [ml],1476.5,5688,DB00292,Etomidate
,31870260,Cmax,"The Cmax after injection with 1.045 mg/kg, 2.09 mg/kg, and 4.18 mg/kg was 1476.5 ± 138.9 ng/ml, 2846.1 ± 223.3 ng/ml, and 6233.3 ± 238.9 ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[ng] / [ml],2846.1,5689,DB00292,Etomidate
,31870260,Cmax,"The Cmax after injection with 1.045 mg/kg, 2.09 mg/kg, and 4.18 mg/kg was 1476.5 ± 138.9 ng/ml, 2846.1 ± 223.3 ng/ml, and 6233.3 ± 238.9 ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[ng] / [ml],6233.3,5690,DB00292,Etomidate
,31870260,t1/2,The t1/2 of the drug was similar across dose groups at 74.8 ± 10.8 min to 81.4 ± 4.2 min.,Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),min,74.8,5691,DB00292,Etomidate
,31870260,t1/2,The t1/2 of the drug was similar across dose groups at 74.8 ± 10.8 min to 81.4 ± 4.2 min.,Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),min,81.4,5692,DB00292,Etomidate
,31870260,AUC0-t,"The AUC0-t values were 30208.1 ± 2026.5 min*ng/ml, 62712.8 ± 1808.3 min*ng/ml, and 130465.2 ± 7457.4 min*ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[min·ng] / [ml],30208.1,5693,DB00292,Etomidate
,31870260,AUC0-t,"The AUC0-t values were 30208.1 ± 2026.5 min*ng/ml, 62712.8 ± 1808.3 min*ng/ml, and 130465.2 ± 7457.4 min*ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[min·ng] / [ml],62712.8,5694,DB00292,Etomidate
,31870260,AUC0-t,"The AUC0-t values were 30208.1 ± 2026.5 min*ng/ml, 62712.8 ± 1808.3 min*ng/ml, and 130465.2 ± 7457.4 min*ng/ml, respectively.",Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870260/),[min·ng] / [ml],130465.2,5695,DB00292,Etomidate
,952578,half-life,"The fast component of the plasma curve, has a half-life of 1.19 min.","Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952578/),min,1.19,6562,DB00292,Etomidate
,6696212,t1,"In group I, mean value for t1 was 37.9 minutes and t2 59.1 minutes which is significantly longer than in group II where mean value for t1 was 9.0 minutes and t2 15.1 minutes.",Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),min,37.9,25532,DB00292,Etomidate
,6696212,t2,"In group I, mean value for t1 was 37.9 minutes and t2 59.1 minutes which is significantly longer than in group II where mean value for t1 was 9.0 minutes and t2 15.1 minutes.",Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),min,59.1,25533,DB00292,Etomidate
,6696212,t1,"In group I, mean value for t1 was 37.9 minutes and t2 59.1 minutes which is significantly longer than in group II where mean value for t1 was 9.0 minutes and t2 15.1 minutes.",Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),min,9.0,25534,DB00292,Etomidate
,6696212,t2,"In group I, mean value for t1 was 37.9 minutes and t2 59.1 minutes which is significantly longer than in group II where mean value for t1 was 9.0 minutes and t2 15.1 minutes.",Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),min,15.1,25535,DB00292,Etomidate
,6696212,plasma clearance,In group I the maintenance level was 501 ng/ml and the plasma clearance 20.9 ml/kg/minute.,Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),[ml] / [kg·min],20.9,25536,DB00292,Etomidate
,6696212,maintenance level,In group II the maintenance level was 367 ng/ml and plasma clearance 27.3 ml/kg/minute.,Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),[ng] / [ml],367,25537,DB00292,Etomidate
,6696212,plasma clearance,In group II the maintenance level was 367 ng/ml and plasma clearance 27.3 ml/kg/minute.,Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6696212/),[ml] / [kg·min],27.3,25538,DB00292,Etomidate
,3582376,T1/2 pi,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,1.24,34526,DB00292,Etomidate
,3582376,T1/2 alpha,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,7.55,34527,DB00292,Etomidate
,3582376,elimination half-life (T1/2 beta,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,86.9,34528,DB00292,Etomidate
,3582376,Vc,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],0.557,34529,DB00292,Etomidate
,3582376,Vc,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],0.274,34530,DB00292,Etomidate
,3582376,distribution volume at steady state (Vss,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],2.52,34531,DB00292,Etomidate
,3582376,total plasma clearance (ClP,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[ml] / [min],1547,34532,DB00292,Etomidate
,3582376,k10,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),1/[min],0.0577,34533,DB00292,Etomidate
,3582376,k10,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),1/[min],0.1093,34534,DB00292,Etomidate
,3582376,Fc,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),,0.08,34535,DB00292,Etomidate
,3582376,Fc,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),,0.19,34536,DB00292,Etomidate
,7212248,plasma half-life,"The plasma half-life of etomidate was in the alpha-phase about 3 minutes, the biological half-life of the beta-phase was about 70 minutes.",[Pharmacokinetics of etomidate in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212248/),min,3,36651,DB00292,Etomidate
,7212248,biological half-life,"The plasma half-life of etomidate was in the alpha-phase about 3 minutes, the biological half-life of the beta-phase was about 70 minutes.",[Pharmacokinetics of etomidate in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212248/),min,70,36652,DB00292,Etomidate
,7212248,total volume of distribution,The total volume of distribution was calculated at 165 litres.,[Pharmacokinetics of etomidate in man (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212248/),l,165,36653,DB00292,Etomidate
,7212248,total plasma clearance,The total plasma clearance amounted to 1600 ml/min.,[Pharmacokinetics of etomidate in man (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212248/),[ml] / [min],1600,36654,DB00292,Etomidate
,34139982,V1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,1.42,42331,DB00292,Etomidate
,34139982,V2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,5.52,42332,DB00292,Etomidate
,34139982,V3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,63.9,42333,DB00292,Etomidate
,34139982,Cl1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.30,42334,DB00292,Etomidate
,34139982,Cl2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.21,42335,DB00292,Etomidate
,34139982,Cl3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],0.584,42336,DB00292,Etomidate
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,275.6-170.9,42389,DB00292,Etomidate
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,217.7-113.1,42390,DB00292,Etomidate
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,172.5-154.3,42391,DB00292,Etomidate
,29149702,terminal phase elimination half-lives,The average terminal phase elimination half-lives were 0.87 and 1.03h for ET-26-HCl and ET-26-acid respectively.,An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),h,0.87,42392,DB00292,Etomidate
,29149702,terminal phase elimination half-lives,The average terminal phase elimination half-lives were 0.87 and 1.03h for ET-26-HCl and ET-26-acid respectively.,An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),h,1.03,42393,DB00292,Etomidate
,7212249,minimal plasma level,The minimal plasma level producing an hypnotic effect was about 0.3 microgram/ml) etomidate.,[Infusion model for etomidate (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212249/),[μg] / [ml],0.3,48811,DB00292,Etomidate
,27537760,Cl1,"The introduction of TOF as a covariate for systemic clearance (Cl1) improved the model and resulted in a significant reduction of objective function (Δobjective function = -7.33; P = .0068), which means that TOF was a significant covariate of Cl1, and the etomidate Cl1 in children with TOF (1.67 × (weight [WT]/70 kg) L/min) was lower than those with normal cardiac anatomy (2.28 × (WT/70 kg) L/min).",Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),[l] / [min],1.67 ×,52023,DB00292,Etomidate
,27537760,Cl1,"The introduction of TOF as a covariate for systemic clearance (Cl1) improved the model and resulted in a significant reduction of objective function (Δobjective function = -7.33; P = .0068), which means that TOF was a significant covariate of Cl1, and the etomidate Cl1 in children with TOF (1.67 × (weight [WT]/70 kg) L/min) was lower than those with normal cardiac anatomy (2.28 × (WT/70 kg) L/min).",Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),[l] / [min],2.28 ×,52024,DB00292,Etomidate
,27537760,V1,Other PK parameter values were as follows: V1 = 8.05 × (WT/70 kg) L; V2 = 13.7 × (WT/70 kg) L; V3 = 41.3 × (WT/70 kg) L; Cl2 = 3.35 × (WT/70 kg) L/min; Cl3 = 0.563 × (WT/70 kg) L/min.,Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),l,8.05 ×,52025,DB00292,Etomidate
,27537760,V2,Other PK parameter values were as follows: V1 = 8.05 × (WT/70 kg) L; V2 = 13.7 × (WT/70 kg) L; V3 = 41.3 × (WT/70 kg) L; Cl2 = 3.35 × (WT/70 kg) L/min; Cl3 = 0.563 × (WT/70 kg) L/min.,Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),l,13.7,52026,DB00292,Etomidate
,27537760,V3,Other PK parameter values were as follows: V1 = 8.05 × (WT/70 kg) L; V2 = 13.7 × (WT/70 kg) L; V3 = 41.3 × (WT/70 kg) L; Cl2 = 3.35 × (WT/70 kg) L/min; Cl3 = 0.563 × (WT/70 kg) L/min.,Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),l,41.3 ×,52027,DB00292,Etomidate
,27537760,Cl2,Other PK parameter values were as follows: V1 = 8.05 × (WT/70 kg) L; V2 = 13.7 × (WT/70 kg) L; V3 = 41.3 × (WT/70 kg) L; Cl2 = 3.35 × (WT/70 kg) L/min; Cl3 = 0.563 × (WT/70 kg) L/min.,Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),[l] / [min],3.35 ×,52028,DB00292,Etomidate
,27537760,Cl3,Other PK parameter values were as follows: V1 = 8.05 × (WT/70 kg) L; V2 = 13.7 × (WT/70 kg) L; V3 = 41.3 × (WT/70 kg) L; Cl2 = 3.35 × (WT/70 kg) L/min; Cl3 = 0.563 × (WT/70 kg) L/min.,Unrepaired Tetralogy of Fallot-related Pathophysiologic Changes Reduce Systemic Clearance of Etomidate in Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537760/),[l] / [min],0.563 ×,52029,DB00292,Etomidate
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,52,52850,DB00292,Etomidate
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,126,52851,DB00292,Etomidate
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,139,52852,DB00292,Etomidate
,2048708,initial midazolam,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52853,DB00292,Etomidate
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52854,DB00292,Etomidate
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],323,52855,DB00292,Etomidate
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],332,52856,DB00292,Etomidate
,697083,initial t1/2,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),min,2.6,58206,DB00292,Etomidate
,697083,intermediate t1/2,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),min,28.7,58207,DB00292,Etomidate
,697083,apparent elimination t1/2,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),h,4.6,58208,DB00292,Etomidate
,697083,volume of the central compartment,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),,23.2,58209,DB00292,Etomidate
,697083,total apparent volume of distribution,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),1/[kg],4.5,58210,DB00292,Etomidate
,697083,fraction of drug in the central compartment,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),%,7,58211,DB00292,Etomidate
,697083,total plasma clearance,"Mean (+/-SD) variables were: initial t1/2, 2.6 +/- 1.3 min; intermediate t1/2, 28.7 +/- 14.0 min; apparent elimination t1/2, 4.6 +/- 2.6 hours; volume of the central compartment, 23.2 +/- 11.41; total apparent volume of distribution, 4.5 +/- 2.21/kg; fraction of drug in the central compartment, 7 per cent; total plasma clearance, 860 +/- 230 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),[ml] / [min],860,58212,DB00292,Etomidate
,697083,Total blood clearance,"Total blood clearance was estimated to be 754 ml/min and hepatic clearance, 739 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),[ml] / [min],754,58213,DB00292,Etomidate
,697083,hepatic clearance,"Total blood clearance was estimated to be 754 ml/min and hepatic clearance, 739 ml/min.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),[ml] / [min],739,58214,DB00292,Etomidate
,697083,hepatic clearance,"The hepatic clearance, being about 50 per cent of hepatic blood flow, indicates that changes in hepatic blood flow or hepatic metabolism will have only moderate effects on etomidate disposition.","Pharmacokinetics of etomidate, a new intravenous anesthetic. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697083/),%,50,58215,DB00292,Etomidate
,17428705,AUC ratio,"After the ETO bolus dose, the fetus:ewe AUC ratio was 0.45+/-0.32, and the mean residence time (MRT) was 20+/-7 min for dams and 22+/-3 min for the fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),,0.45,61925,DB00292,Etomidate
,17428705,mean residence time (MRT),"After the ETO bolus dose, the fetus:ewe AUC ratio was 0.45+/-0.32, and the mean residence time (MRT) was 20+/-7 min for dams and 22+/-3 min for the fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),min,20,61926,DB00292,Etomidate
,17428705,mean residence time (MRT),"After the ETO bolus dose, the fetus:ewe AUC ratio was 0.45+/-0.32, and the mean residence time (MRT) was 20+/-7 min for dams and 22+/-3 min for the fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),min,22,61927,DB00292,Etomidate
,17428705,AUC ratio,"After ETO infusion, the AUC ratio was 0.37+/-0.08, and MRT was 46+/-12 min for ewes and 46+/-22 min for fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),,0.37,61928,DB00292,Etomidate
,17428705,MRT,"After ETO infusion, the AUC ratio was 0.37+/-0.08, and MRT was 46+/-12 min for ewes and 46+/-22 min for fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),min,46,61929,DB00292,Etomidate
,17428705,MRT,"After ETO infusion, the AUC ratio was 0.37+/-0.08, and MRT was 46+/-12 min for ewes and 46+/-22 min for fetuses.",Placental transfer of etomidate in pregnant ewes after an intravenous bolus dose and continuous infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428705/),min,46,61930,DB00292,Etomidate
,6869754,steady state plasma concentration,The steady state plasma concentration associated with the technique which produced the required degree of sedation was found to be 158 micrograms/litre (SEM 36).,Plasma concentrations of etomidate during an intravenous infusion over 48 hours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869754/),[μg] / [l],158,64425,DB00292,Etomidate
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00292,Etomidate
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00292,Etomidate
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00292,Etomidate
,3921471,elimination half-life,The kinetics of the analgesic can be described by a two-compartment model; the elimination half-life has a mean value of 64.8 +/- 38.5 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,64.8,86281,DB00292,Etomidate
,3921471,elimination half-life,The mean elimination half-life is 29.4 +/- 6.2 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,29.4,86282,DB00292,Etomidate
,9447861,peak concentrations,"Mean peak concentrations occurred 20-30 min later and ranged from 61-174 ng/ml, related to the dose administered.",Oral transmucosal etomidate in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447861/),[ng] / [ml],61-174,95276,DB00292,Etomidate
,12667178,volumes of distribution at steady state (Vd(ss)),"Following intravenous administration, the volumes of distribution at steady state (Vd(ss)) were 0.21 L/kg (halibut) and 0.44 L/kg (turbot).",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[l] / [kg],0.21,99842,DB00292,Etomidate
,12667178,volumes of distribution at steady state (Vd(ss)),"Following intravenous administration, the volumes of distribution at steady state (Vd(ss)) were 0.21 L/kg (halibut) and 0.44 L/kg (turbot).",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[l] / [kg],0.44,99843,DB00292,Etomidate
,12667178,Plasma clearances (Cl),"Plasma clearances (Cl) were 0.099 L/h.kg in halibut and 0.26 L/h.kg in turbot and the elimination half-lives (t(1/2)lambdaz) were calculated to be 5.8 h and 2.2 h in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[l] / [h·kg],0.099,99844,DB00292,Etomidate
,12667178,Plasma clearances (Cl),"Plasma clearances (Cl) were 0.099 L/h.kg in halibut and 0.26 L/h.kg in turbot and the elimination half-lives (t(1/2)lambdaz) were calculated to be 5.8 h and 2.2 h in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[l] / [h·kg],0.26,99845,DB00292,Etomidate
,12667178,elimination half-lives (t(1/2)lambdaz),"Plasma clearances (Cl) were 0.099 L/h.kg in halibut and 0.26 L/h.kg in turbot and the elimination half-lives (t(1/2)lambdaz) were calculated to be 5.8 h and 2.2 h in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),h,5.8,99846,DB00292,Etomidate
,12667178,elimination half-lives (t(1/2)lambdaz),"Plasma clearances (Cl) were 0.099 L/h.kg in halibut and 0.26 L/h.kg in turbot and the elimination half-lives (t(1/2)lambdaz) were calculated to be 5.8 h and 2.2 h in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),h,2.2,99847,DB00292,Etomidate
,12667178,Mean residence times (MRT),Mean residence times (MRT) were 2.2 h in halibut and 1.7 h in turbot.,Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),h,2.2,99848,DB00292,Etomidate
,12667178,Mean residence times (MRT),Mean residence times (MRT) were 2.2 h in halibut and 1.7 h in turbot.,Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),h,1.7,99849,DB00292,Etomidate
,12667178,t(1/2)lambdaz,"Following oral administration, the t(1/2)lambdaz was 3.5 h in turbot.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),h,3.5,99850,DB00292,Etomidate
,12667178,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) was 7.8 mg/L in turbot 1 h after administration.,Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[mg] / [l],7.8,99851,DB00292,Etomidate
,12667178,oral bioavailability (F),The oral bioavailability (F) was calculated to 100% in turbot.,Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),%,100,99852,DB00292,Etomidate
,12667178,maximum plasma concentrations (Cmax),"Following 5 min bath the maximum plasma concentrations (Cmax), which were observed immediately after end of the bath, were 9.5 mg/L and 13.3 mg/L in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[mg] / [l],9.5,99853,DB00292,Etomidate
,12667178,maximum plasma concentrations (Cmax),"Following 5 min bath the maximum plasma concentrations (Cmax), which were observed immediately after end of the bath, were 9.5 mg/L and 13.3 mg/L in halibut and turbot, respectively.",Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667178/),[mg] / [l],13.3,99854,DB00292,Etomidate
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,6.34,133161,DB00292,Etomidate
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.85,133162,DB00292,Etomidate
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.10,133163,DB00292,Etomidate
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,8.16,133164,DB00292,Etomidate
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,9.47,133165,DB00292,Etomidate
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,10.0,133166,DB00292,Etomidate
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.0,133167,DB00292,Etomidate
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.4,133168,DB00292,Etomidate
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.6,133169,DB00292,Etomidate
,3379665,total plasma clearance,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[ml] / [kg·min],31.1,133529,DB00292,Etomidate
,3379665,total plasma clearance,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[ml] / [kg·min],21.9,133530,DB00292,Etomidate
,3379665,volume of distribution,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[l] / [kg],3.78,133531,DB00292,Etomidate
,3379665,volume of distribution,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[l] / [kg],2.23,133532,DB00292,Etomidate
,1755554,apparent plateau phase (steady state),Those measured during the apparent plateau phase (steady state) of infusion protocol B were close to predicted values (0.5 to 0.6 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μg,0.5 to 0.6,138071,DB00292,Etomidate
,1755554,time interval to spontaneous recovery,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),min,41,138072,DB00292,Etomidate
,1755554,plasma levels,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μ,0.199,138073,DB00292,Etomidate
,3304768,half-life,"Dexamethasone is rapidly eliminated, the short half-life (about 3 hours) indicating that dosage intervals should be kept small.",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,3,143709,DB00292,Etomidate
,3304768,elimination half-life,"Following single doses, pentobarbitone has a relatively long elimination half-life (about 22 hours).",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,22,143710,DB00292,Etomidate
,6340709,plasma terminal half-life,"The plasma terminal half-life was found to be about 5.5 h, and the clearance calculated to be 0.025 litre kg-1 min-1.",Pharmacokinetics of etomidate associated with prolonged i.v. infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6340709/),h,5.5,157956,DB00292,Etomidate
,6340709,clearance,"The plasma terminal half-life was found to be about 5.5 h, and the clearance calculated to be 0.025 litre kg-1 min-1.",Pharmacokinetics of etomidate associated with prolonged i.v. infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6340709/),[l] / [kg·min],0.025,157957,DB00292,Etomidate
,6548357,rectal systemic availabilities,The results showed that the mean rectal systemic availabilities calculated according to the AUC method and the deconvolution method were considerably higher (70.1% and 67.6% respectively) as compared to the mean values following oral administration (4.5% and 9.2% respectively).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),%,70.1,165516,DB00292,Etomidate
,6548357,rectal systemic availabilities,The results showed that the mean rectal systemic availabilities calculated according to the AUC method and the deconvolution method were considerably higher (70.1% and 67.6% respectively) as compared to the mean values following oral administration (4.5% and 9.2% respectively).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),%,67.6,165517,DB00292,Etomidate
,6548357,rectal systemic availabilities,The results showed that the mean rectal systemic availabilities calculated according to the AUC method and the deconvolution method were considerably higher (70.1% and 67.6% respectively) as compared to the mean values following oral administration (4.5% and 9.2% respectively).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),%,4.5,165518,DB00292,Etomidate
,6548357,rectal systemic availabilities,The results showed that the mean rectal systemic availabilities calculated according to the AUC method and the deconvolution method were considerably higher (70.1% and 67.6% respectively) as compared to the mean values following oral administration (4.5% and 9.2% respectively).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),%,9.2,165519,DB00292,Etomidate
,6548357,maximal rate of absorption,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[μg] / [h],5343,165520,DB00292,Etomidate
,6548357,maximal rate of absorption,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),h,0.13,165521,DB00292,Etomidate
,6548357,maximal rate of absorption,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[μg] / [h],600,165522,DB00292,Etomidate
,6548357,maximal rate of absorption,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),h,0.23,165523,DB00292,Etomidate
,6548357,time at which this,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[μg] / [h],5343,165524,DB00292,Etomidate
,6548357,time at which this,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),h,0.13,165525,DB00292,Etomidate
,6548357,time at which this,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[μg] / [h],600,165526,DB00292,Etomidate
,6548357,time at which this,It showed that the mean maximal rate of absorption was higher and the time at which this occurred was shorter after rectal (5343 micrograms/hr and 0.13 hr) than after oral (600 micrograms/hr and 0.23 hr) administration.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),h,0.23,165527,DB00292,Etomidate
,6548357,blood elimination half-lives,Mean blood elimination half-lives following rectal administration (112.6 min) were longer than that after i.a. administration (61.7 min).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),min,112.6,165528,DB00292,Etomidate
,6548357,blood elimination half-lives,Mean blood elimination half-lives following rectal administration (112.6 min) were longer than that after i.a. administration (61.7 min).,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),min,61.7,165529,DB00292,Etomidate
,6548357,half-life,The mean half-life of 22.8 min after oral administration should be considered as a distribution half-life.,"Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),min,22.8,165530,DB00292,Etomidate
,6548357,clearance,"The mean clearance following i.a. administration was 35.2 ml/min (142.7 ml/min/kg), which is higher than hepatic bloodflow and indicates extra-hepatic metabolism.","Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[ml] / [min],35.2,165531,DB00292,Etomidate
,6548357,clearance,"The mean clearance following i.a. administration was 35.2 ml/min (142.7 ml/min/kg), which is higher than hepatic bloodflow and indicates extra-hepatic metabolism.","Rectal, oral and I.A. administration of etomidate to rats: significant avoidance of hepatic first-pass elimination following rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548357/),[ml] / [kg·min],142.7,165532,DB00292,Etomidate
,6869758,half-life,The postinfusion plasma etomidate concentration was described by a three compartment model with a mean half-life of 540 minutes (SEM 66.9) and volume of distribution of 8.9 litres/kg (SEM 0.6).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),min,540,182304,DB00292,Etomidate
,6869758,volume of distribution,The postinfusion plasma etomidate concentration was described by a three compartment model with a mean half-life of 540 minutes (SEM 66.9) and volume of distribution of 8.9 litres/kg (SEM 0.6).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),[l] / [kg],8.9,182305,DB00292,Etomidate
,6869758,Clearance,Clearance was 12.7 ml/kg/minute (SEM 2.3).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),[ml] / [kg·min],12.7,182306,DB00292,Etomidate
,2363548,octanol/water partition coefficient,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,1000,182659,DB00292,Etomidate
,2363548,pKa,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,4.5,182660,DB00292,Etomidate
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,2.6,182661,DB00292,Etomidate
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182662,DB00292,Etomidate
,2363548,terminal elimination half-life,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),h,4-5,182663,DB00292,Etomidate
,2363548,t1/2,Hypnotic plasma concentrations (greater than 0.2 microgram.ml-1) are observed during the intermediate distribution phase (t1/2 approximately 20 min); they reflect the short lasting pharmacodynamic effect.,[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182664,DB00292,Etomidate
,7224720,distribution half-life,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),min,2.8,197256,DB00292,Etomidate
,7224720,half-life of the alpha-phase,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),min,22.3,197257,DB00292,Etomidate
,7224720,half-life of the beta-phase,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),min,208.8,197258,DB00292,Etomidate
,7224720,distribution volume,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),[l] / [kg],3.68,197259,DB00292,Etomidate
,7224720,Vd area,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),[l] / [kg],3.68,197260,DB00292,Etomidate
,7224720,Vdss,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),[l] / [kg],2.16,197261,DB00292,Etomidate
,7224720,plasma clearance,"The following mean parameters were computed: distribution half-life 2.8 + or - 2.3 min, half-life of the alpha-phase: 22.3 +or - 10.4 min and half-life of the beta-phase 208.8 + or - 64.9 min, distribution volume 3.68 + or - 0.66 l.kg(-1) (Vd area) and 2.16 l.kg(-1) (Vdss) and plasma clearance 879 + or - 135 ml.min(-1).",Pharmacokinetics of etomidate in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224720/),[ml] / [min],879,197262,DB00292,Etomidate
,2155718,t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,7.6,199052,DB00292,Etomidate
,2155718,terminal phase (t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,161,199053,DB00292,Etomidate
,2155718,central compartment volume,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg],102,199054,DB00292,Etomidate
,2155718,plasma clearance,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg·min],1.8,199055,DB00292,Etomidate
,9585308,maximal serum etomidate concentration,The mean (+/- SD) maximal serum etomidate concentration after buccal mucosal absorption from the 50-mg dose unit was 239 +/- 79 ng/mL.,Buccal absorption of etomidate from a solid formulation in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),[ng] / [ml],239,202808,DB00292,Etomidate
,9585308,time to reach maximal serum concentration,The time to reach maximal serum concentration was 12.5 +/- 1.8 min.,Buccal absorption of etomidate from a solid formulation in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),min,12.5,202809,DB00292,Etomidate
,9585308,Peak absorption rate,Peak absorption rate of etomidate into the systemic circulation was 832 +/- 417 microg/min.,Buccal absorption of etomidate from a solid formulation in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),[μg] / [min],832,202810,DB00292,Etomidate
,9585308,apparent transbuccal mucosal permeability coefficient,"The apparent transbuccal mucosal permeability coefficient was 9.1 +/- 4.2 x 10(-4) cm/s, higher than values of any other compounds examined.",Buccal absorption of etomidate from a solid formulation in dogs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),[cm] / [s],9.1,202811,DB00292,Etomidate
,9585308,Bioavailability,"Bioavailability calculated using the area under the serum etomidate concentration versus time curve method and the deconvolution method was 13.6% +/- 10.7% and 16.6% +/- 7.6%, respectively.",Buccal absorption of etomidate from a solid formulation in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),%,13.6,202812,DB00292,Etomidate
,9585308,Bioavailability,"Bioavailability calculated using the area under the serum etomidate concentration versus time curve method and the deconvolution method was 13.6% +/- 10.7% and 16.6% +/- 7.6%, respectively.",Buccal absorption of etomidate from a solid formulation in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585308/),%,16.6,202813,DB00292,Etomidate
,25377074,central,"The study population was found to have a central and intercompartmental clearance of 0.624 l/min/70 kg and 0.44 l/min/70 kg, respectively; central and peripheral distribution volume of 9.47 l/70 kgand 22.8 l/70 kg, respectively.",Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377074/),[l] / [70·kg·min],0.624,207826,DB00292,Etomidate
,25377074,intercompartmental clearance,"The study population was found to have a central and intercompartmental clearance of 0.624 l/min/70 kg and 0.44 l/min/70 kg, respectively; central and peripheral distribution volume of 9.47 l/70 kgand 22.8 l/70 kg, respectively.",Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377074/),[l] / [70·kg·min],0.44,207827,DB00292,Etomidate
,25377074,central,"The study population was found to have a central and intercompartmental clearance of 0.624 l/min/70 kg and 0.44 l/min/70 kg, respectively; central and peripheral distribution volume of 9.47 l/70 kgand 22.8 l/70 kg, respectively.",Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377074/),[l] / [70·kg],9.47,207828,DB00292,Etomidate
,25377074,peripheral distribution volume,"The study population was found to have a central and intercompartmental clearance of 0.624 l/min/70 kg and 0.44 l/min/70 kg, respectively; central and peripheral distribution volume of 9.47 l/70 kgand 22.8 l/70 kg, respectively.",Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377074/),[l] / [70·kg],22.8,207829,DB00292,Etomidate
,2675669,Plasma levels,Plasma levels in group I decreased from 630 ng/ml after 2 min to 170 after 8 min and 37 after 130 min.,[A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675669/),[ng] / [ml],630,219963,DB00292,Etomidate
,2675669,Plasma levels,Plasma levels in group I decreased from 630 ng/ml after 2 min to 170 after 8 min and 37 after 130 min.,[A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675669/),,170,219964,DB00292,Etomidate
,2675669,Plasma levels,Plasma levels in group I decreased from 630 ng/ml after 2 min to 170 after 8 min and 37 after 130 min.,[A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675669/),,37,219965,DB00292,Etomidate
,2675669,plasma,With group II the plasma levels decreased from 770 ng/ml after 2 min to 150 after 8 min and 42 after 130 min (Fig. 1).,[A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675669/),,77,219966,DB00292,Etomidate
,4029127,slope,"Etomidate was administered to six healthy volunteers by microprocessor controlled infusions, to generate three cycles of linearly increasing plasma levels, with an anticipated slope of 0.05 microgram ml-1 min-1.",Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029127/),,0,222008,DB00292,Etomidate
,4029127,volume for the central compartment,"Pharmacokinetic analysis gave a volume for the central compartment of 50 +/- 11 litre, an apparent volume of distribution of 252 +/- 51 litre and a total clearance of 1693 +/- 504 ml min-1.",Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029127/),l,50,222009,DB00292,Etomidate
,4029127,apparent volume of distribution,"Pharmacokinetic analysis gave a volume for the central compartment of 50 +/- 11 litre, an apparent volume of distribution of 252 +/- 51 litre and a total clearance of 1693 +/- 504 ml min-1.",Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029127/),l,252,222010,DB00292,Etomidate
,4029127,total clearance,"Pharmacokinetic analysis gave a volume for the central compartment of 50 +/- 11 litre, an apparent volume of distribution of 252 +/- 51 litre and a total clearance of 1693 +/- 504 ml min-1.",Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029127/),[ml] / [min],1693,222011,DB00292,Etomidate
,6135368,plasma concentrations,Alfentanil plasma concentrations of 0.45 microgram/ml were maintained by the same infusion scheme beginning with skin incision until 20 minutes prior to the end of surgery.,Pharmacokinetics as applied to total intravenous anaesthesia. Practical implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135368/),[μg] / [ml],0.45,230377,DB00292,Etomidate
,6824149,recovery times,"The basic dose schedule provided adequate surgical anaesthesia for 76% of patients (although dose adjustments were used in the remainder), with recovery times of 10 minutes or less in 57% of patients.",Total intravenous anaesthesia with etomidate-fentanyl. Use in general and gynaecological surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824149/),min,10,238660,DB00292,Etomidate
,33960250,particle,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),,168.0,242640,DB00292,Etomidate
,33960250,polydispersity index,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),,0.108,242641,DB00292,Etomidate
,33960250,zeta potential,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),mv,-,242642,DB00292,Etomidate
,33960250,zeta potential,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),mv,36.4,242643,DB00292,Etomidate
,33960250,drug loading,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),[mg] / [ml],2.00,242644,DB00292,Etomidate
,33960250,encapsulation efficiency,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),%,97.65,242645,DB00292,Etomidate
,33960250,osmotic pressure,"The optimized formulation had the following characteristics: particle size, 168.0 ± 0.3 nm; polydispersity index, 0.108 ± 0.028; zeta potential, -36.4 ± 0.2 mV; drug loading, 2.00 ± 0.01 mg/mL; encapsulation efficiency, 97.65% ± 0.16%; osmotic pressure, 292 ± 2 mOsmol/kg and pH value, 7.63 ± 0.07.","Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960250/),[mosmol] / [kg],292,242646,DB00292,Etomidate
,25170571,ED50,"Compared with etomidate, CPMM was half as potent as a hypnotic (ED50 approximately 0.8 mg/kg), was more rapidly metabolized, and had a shorter duration of sedative-hypnotic action.",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),[mg] / [kg],0.8,248749,DB00292,Etomidate
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,215,248750,DB00292,Etomidate
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,"1,623",248751,DB00292,Etomidate
,21917057,Cl(1),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),[l] / [min],1.50,248993,DB00292,Etomidate
,21917057,Cl(2),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),[l] / [min],1.95,248994,DB00292,Etomidate
,21917057,Cl(3),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),[l] / [min],1.23,248995,DB00292,Etomidate
,21917057,V(1),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),l,9.51,248996,DB00292,Etomidate
,21917057,V(2),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),l,11.0,248997,DB00292,Etomidate
,21917057,V(3),"The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.",Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917057/),l,79.2,248998,DB00292,Etomidate
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.66,258834,DB00292,Etomidate
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.27,258835,DB00292,Etomidate
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,5.4,258836,DB00292,Etomidate
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,2.7,258837,DB00292,Etomidate
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],17.2,258838,DB00292,Etomidate
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],10.9,258839,DB00292,Etomidate
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,37.1,258840,DB00292,Etomidate
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,26.8,258841,DB00292,Etomidate
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,260,258842,DB00292,Etomidate
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,175,258843,DB00292,Etomidate
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.5,258844,DB00292,Etomidate
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.8,258845,DB00292,Etomidate
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.1,258846,DB00292,Etomidate
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.0,258847,DB00292,Etomidate
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,228,258848,DB00292,Etomidate
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,172,258849,DB00292,Etomidate
,4029126,slope,Six volunteers were subjected to an infusion of etomidate designed to generate linearly increasing plasma concentrations with a slope of 0.05 microgram ml-1 min-1.,Quantitation of the EEG and pharmacodynamic modelling of hypnotic drugs: etomidate as an example. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029126/),,0,260726,DB00292,Etomidate
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,301,262732,DB00292,Etomidate
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,307,262733,DB00292,Etomidate
,8273922,plasma concentrations,"At the time, plasma concentrations of F and S were 1.35 +/- 0.9 ng.",[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),ng,1.35,262734,DB00292,Etomidate
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,457,262735,DB00292,Etomidate
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,325,262736,DB00292,Etomidate
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB00292,Etomidate
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB00292,Etomidate
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB00292,Etomidate
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB00292,Etomidate
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB00292,Etomidate
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB00292,Etomidate
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB00292,Etomidate
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB00292,Etomidate
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB00292,Etomidate
,20498288,volumes of distribution at central,"A 2-compartment pharmacokinetic model and a pharmacodynamic sigmoid E(max) model fit the data best, with volumes of distribution at central and peripheral compartments of 4.45 and 74.90 L, respectively, and systemic and intercompartmental clearances of 0.63 and 3.16 L/min, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),l,4.45,271998,DB00292,Etomidate
,20498288,systemic,"A 2-compartment pharmacokinetic model and a pharmacodynamic sigmoid E(max) model fit the data best, with volumes of distribution at central and peripheral compartments of 4.45 and 74.90 L, respectively, and systemic and intercompartmental clearances of 0.63 and 3.16 L/min, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),[l] / [min],0.63,271999,DB00292,Etomidate
,20498288,intercompartmental clearances,"A 2-compartment pharmacokinetic model and a pharmacodynamic sigmoid E(max) model fit the data best, with volumes of distribution at central and peripheral compartments of 4.45 and 74.90 L, respectively, and systemic and intercompartmental clearances of 0.63 and 3.16 L/min, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),[l] / [min],0.63,272000,DB00292,Etomidate
,20498288,intercompartmental clearances,"A 2-compartment pharmacokinetic model and a pharmacodynamic sigmoid E(max) model fit the data best, with volumes of distribution at central and peripheral compartments of 4.45 and 74.90 L, respectively, and systemic and intercompartmental clearances of 0.63 and 3.16 L/min, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),[l] / [min],3.16,272001,DB00292,Etomidate
,20498288,t(1/2)k(e0),t(1/2)k(e0) was 1.550 min.,Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),min,1.550,272002,DB00292,Etomidate
,20498288,EC(50),"EC(50) values were 0.526 and 0.554 µg/mL, and gamma values were 2.25 and 6.24 for BIS and OAA/S, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),[μg] / [ml],0.526,272003,DB00292,Etomidate
,20498288,EC(50),"EC(50) values were 0.526 and 0.554 µg/mL, and gamma values were 2.25 and 6.24 for BIS and OAA/S, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),[μg] / [ml],0.554,272004,DB00292,Etomidate
,20498288,gamma,"EC(50) values were 0.526 and 0.554 µg/mL, and gamma values were 2.25 and 6.24 for BIS and OAA/S, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),,2.25,272005,DB00292,Etomidate
,20498288,gamma,"EC(50) values were 0.526 and 0.554 µg/mL, and gamma values were 2.25 and 6.24 for BIS and OAA/S, respectively.",Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498288/),,6.24,272006,DB00292,Etomidate
,2301840,distribution half-life,The first and most rapid distribution half-life was 0.05 hour and a second distribution half-life was 0.35 hour.,Pharmacokinetics of etomidate in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),h,0.05,274195,DB00292,Etomidate
,2301840,distribution half-life,The first and most rapid distribution half-life was 0.05 hour and a second distribution half-life was 0.35 hour.,Pharmacokinetics of etomidate in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),h,0.35,274196,DB00292,Etomidate
,2301840,Elimination half-life,"Elimination half-life was 2.89 hours, apparent volume of distribution was 11.87 +/- 4.64 L/kg, apparent volume of distribution at steady state was 4.88 +/- 2.25 L/kg, apparent volume of the central compartment was 1.17 +/- 0.70 L/kg, and total clearance was 2.47 +/- 0.78 L/kg/h.",Pharmacokinetics of etomidate in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),h,2.89,274197,DB00292,Etomidate
,2301840,apparent volume of distribution,"Elimination half-life was 2.89 hours, apparent volume of distribution was 11.87 +/- 4.64 L/kg, apparent volume of distribution at steady state was 4.88 +/- 2.25 L/kg, apparent volume of the central compartment was 1.17 +/- 0.70 L/kg, and total clearance was 2.47 +/- 0.78 L/kg/h.",Pharmacokinetics of etomidate in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),[l] / [kg],11.87,274198,DB00292,Etomidate
,2301840,apparent volume of distribution at steady state,"Elimination half-life was 2.89 hours, apparent volume of distribution was 11.87 +/- 4.64 L/kg, apparent volume of distribution at steady state was 4.88 +/- 2.25 L/kg, apparent volume of the central compartment was 1.17 +/- 0.70 L/kg, and total clearance was 2.47 +/- 0.78 L/kg/h.",Pharmacokinetics of etomidate in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),[l] / [kg],4.88,274199,DB00292,Etomidate
,2301840,apparent volume of the central compartment,"Elimination half-life was 2.89 hours, apparent volume of distribution was 11.87 +/- 4.64 L/kg, apparent volume of distribution at steady state was 4.88 +/- 2.25 L/kg, apparent volume of the central compartment was 1.17 +/- 0.70 L/kg, and total clearance was 2.47 +/- 0.78 L/kg/h.",Pharmacokinetics of etomidate in cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),[l] / [kg],1.17,274200,DB00292,Etomidate
,2301840,total clearance,"Elimination half-life was 2.89 hours, apparent volume of distribution was 11.87 +/- 4.64 L/kg, apparent volume of distribution at steady state was 4.88 +/- 2.25 L/kg, apparent volume of the central compartment was 1.17 +/- 0.70 L/kg, and total clearance was 2.47 +/- 0.78 L/kg/h.",Pharmacokinetics of etomidate in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301840/),[l] / [h·kg],2.47,274201,DB00292,Etomidate
